KR830001415B1 - Process for preparing cephalosporin derivatives - Google Patents

Process for preparing cephalosporin derivatives Download PDF

Info

Publication number
KR830001415B1
KR830001415B1 KR7701971A KR770001971A KR830001415B1 KR 830001415 B1 KR830001415 B1 KR 830001415B1 KR 7701971 A KR7701971 A KR 7701971A KR 770001971 A KR770001971 A KR 770001971A KR 830001415 B1 KR830001415 B1 KR 830001415B1
Authority
KR
South Korea
Prior art keywords
water
carboxylic acid
added
2hci
dried
Prior art date
Application number
KR7701971A
Other languages
Korean (ko)
Other versions
KR830000250A (en
Inventor
겐조오 나이또오
가즈오 쓰가무라
신뽀하루오
Original Assignee
다데오까 스에오오
다케다 야꾸힝고오교오 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다데오까 스에오오, 다케다 야꾸힝고오교오 가부시기가이샤 filed Critical 다데오까 스에오오
Priority to KR7701971A priority Critical patent/KR830001415B1/en
Publication of KR830000250A publication Critical patent/KR830000250A/en
Application granted granted Critical
Publication of KR830001415B1 publication Critical patent/KR830001415B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36Methylene radicals, substituted by sulfur atoms

Abstract

The solid, storage stable cephalosporin salts I(X=Cl,Br; n=0-6) were prepd. by treating H2NCH2CH2NMe2 with CS2, conveting Me2NCH2CH2NHCS2H to its Me ester, and cyclizing the latter with NaN3 to the tetrazolethiol II. Reaction of the acetoxymethylcephem III with II, followed by treatment with 12N HCl gave 94% pure I(X=Cl, n=1). The MIC of stepilococus aureus FDA 209p and toxicity of mice were 0.39mcg/ml and CD 50>=20 g/kg, resp.

Description

세팔로스포린 유도체의 제조방법Method for preparing cephalosporin derivative

본 발명은 다음 일반식(I)로 표시되는 고형상 세파로스포린 유도체의 제조방법에 관한 것이다.The present invention relates to a method for producing a solid Sepharoseporin derivative represented by the following general formula (I).

Figure kpo00001
Figure kpo00001

(상기식중, X는 염소 또는 취소를, n은 0내지 6의 수를 표시한다)(Wherein X represents chlorine or cancellation and n represents a number from 0 to 6)

종래부터 다음일반식(II)로 표시되는 화합물이 우수한 항균력을 가지고 있다는 것은 공지의 사실이나, (서독일 공개공보 제2461478호) 화합물(II)는 분자내에 아미노치아조린기, 디메틸아미노기의 2개의 염기성기 및 1개의 카르복실기를 갖고 있기 때문에, 극히 수용성이 강하고, 정제하기 어려울 뿐만아니라 보존에 있어서 충분히 안정하다고 말하기 어려운 결점이 있다.It is well known that the compound represented by the following general formula (II) has excellent antibacterial ability in the past, but (West German Publication No. 2461478) Compound (II) has two amino thiazoline groups and dimethylamino group in the molecule. Since it has a basic group and one carboxyl group, there exists a fault which is extremely water solubility, difficult to refine | purify, and hard to say that it is sufficiently stable in storage.

Figure kpo00002
Figure kpo00002

이점을 개선하려고 연구를 거듭한 결과, 화합물(II)과 2몰 이상의 식 HX(식중 X는 상기와 같다)로서 표시되는 산과, 필요하면, 물의 존재하에 반응시키면 고형상 세파로스포린 유도체(I)을 얻을 수 있다는것, 그리고 얻어진 화합물(I)이 보존함에 있어서 대단히 안정하고 또한 화합물(I)은 결정으로 취득할 수 있는 경우에는 종래의 정제방법으로는 제거가 곤란하였던 불순물이 거의 완전히 제거된다는 사실을 발견하고, 이를 토대로 본 발명을 완성했다. 즉, 본 발명은,As a result of repeated studies to improve the advantages, the solid cephalosporin derivative (I) is reacted with a compound (II) and an acid represented by two or more moles of formula HX (wherein X is the same as above), if necessary, in the presence of water. The fact that the obtained compound (I) is extremely stable in preservation and that the compound (I) can be obtained as a crystal can almost completely remove impurities which were difficult to remove by the conventional purification method. The present invention was completed based on this finding. That is, the present invention,

(1) 고형상 세팔로스포린 유도체(I)(1) Solid Cephalosporin Derivatives (I)

(2) 화합물(II)과 2몰 이상의 식 HX로서 표시되는 산과를 필요하면 물의 존재하에 반응시키는 것을 특징으로 하는 고형상 세팔로스포린 유도체(I)의 제조방법에 관한 것이다.(2) A method for producing a solid cephalosporin derivative (I) characterized by reacting a compound (II) with an acid represented by the formula HX of 2 moles or more in the presence of water if necessary.

상기일반식(I)중, x는 염소 또는 취소를 표시한다. 상기일반식(I)의 화합물은 6이하의 물분자를 함유한다. 그중에서도 특히, 1수화물에서 6수화물의 6종류의 수화물이 존재하는 바, 제조조건에 따라 1몰이하의 결합을 함유하는 경우가 있으며, 어느것이든 결정으로서 채취된다. 무수물은 통상 비결정형분말이지만 1물 이하의 결합수를 갖고 있어도 좋다. 이들은 어느것이나 본 발명의 범위에 속한다. n의 범위로서 0.1

Figure kpo00003
n
Figure kpo00004
4인 것은 안정성, 순도에 있어서 가장 바람직하다.In the general formula (I), x represents chlorine or cancellation. The compound of general formula (I) contains water molecules of 6 or less. Among them, six kinds of hydrates, particularly monohydrate to hexahydrate, exist, which may contain 1 mole or less of bonds depending on the production conditions, and any of them are collected as crystals. Anhydrides are usually amorphous powders, but may have a bonding water of one or less. All of these belong to the scope of the present invention. 0.1 as the range of n
Figure kpo00003
n
Figure kpo00004
4 is the most preferable in stability and purity.

본 발명은, 원료화합물(II)과 2몰 이상의 식 HX로서 표시되는 산과를 필요하면 물의 존재하에 반응시키므로써 행해진다. 원료화합물(II)은, 예를들면 원료화합물(II)의 합성반응 혼합액자체 혹은 반응혼합액으로 부터 대부분의 불술물을 제거한 용액, 이 용액과 난용성 용매와의 혼합에 의해서 취득되는 분말 혹은 이 용액을 농축건고 또는 동결건조하여 얻어지는 분말등이 사용된다. 원료화합물(II)은 양성(쌍성:zwitter)이온, 나트륨등의 알카리 금속염들으로서 본 반응에 제공할 수가 있다.The present invention is carried out by reacting a raw material compound (II) with an acid represented by two or more moles of formula HX in the presence of water if necessary. The starting compound (II) is, for example, a solution obtained by removing most of the impurities from the synthesis reaction mixture liquid or the reaction mixture of the starting compound (II), a powder obtained by mixing the solution with a poorly soluble solvent, or the solution. Powder obtained by concentrated drying or lyophilization is used. The starting compound (II) can be used in the present reaction as alkali metal salts such as zwitter ions and sodium.

식 HX로서 표시되는 산으로서는, 염화수소산, 취화수소산이 사용된다, 산의 사용량은, 원료(II) 1몰에 대하여 2몰보다 적으면 균일한 결정을 얻는 것이 상당히 곤란하며 너무나 많이 사용하면 원료(II)의 분해가 일어나기 때문에, 통상 2-10몰 바람직하기는 2-6몰이다. 반응은, 조작성, 수율, 정제효과등의 점에서 유리하게 진행하도록, 보통 물 또는 유기용매 혹은 이들의 혼합용매의 존재하에 행하여 진다. 반응에 용되는 유기용매로는,예를들면 에탄올, n-프로판올, 이소프로판올, 부탄올,이소부타올, 아세톤, 메틸에틸케톤, 아세토니트릴, 테트라히드로푸란, 디옥산등 목적물(I)이 난용성이며 또한 물에 용해될 수 있는 용매 이외에, 이들의 용매와 목적물(I)이 쉽게 용해되고 또한 물에 용해될 수 있는 예를 들면메탄올, 디메틸설폭시드, 포름아미드, N,N-디메틸포름아미드, N,N-디메틸아세트아미드, 메틸셀루로솔브등의 용매와의 혼합용매 혹은 이들 용매와 목적물(I)이 난용성(難溶性)이며 또한 물에 용해되기 어러운 예를들면 초산에틸, 에테르, 디클로르메탄, 클로로포름등의 용매와의 혼합용매등이 사용된다. 그중에서도, 예를 들면 물과 아세톤, 에탄올, n-프로판올, i-프로판올, 메틸에틸케톤 또는 테트라 히드로푸란과의 혼합용매등의 매우 적합하다. 반응온도는 보통-10-40℃바람직하게는 0-30℃의 온도범위에서 시행된다. -10℃이하에서는 결정의 성장속도가 늦고 조작할때 냉각이 팔요하며, 40℃ 이상에서는 원료(II)의 분해반응이 일어나므로 불리하다. 반응시간은, 사용되는 원료(II)의 순도 및 함유되는 불순물의 종류에 따라 다르지만, 통상의 정제방법 예를들면 흡착제등에 의해 컬럼크로마토그래피에 의하여 정제된 순도 80%이상의 원료(II)를 사용한 경우에는 30분-24시간 바람직하게는 30분-4시간이다. 반생성물(I)은, 여과 또는 원심분리, 동결전조등으로 단리(單離)된다. 단리된 화합물(I)중에 유기용매가 함유되는 경우에는, 유기용매를 제거하고 필요에 따라 건조시킨다.As the acid represented by the formula HX, hydrochloric acid and hydrobromic acid are used. When the amount of acid used is less than 2 moles with respect to 1 mole of raw material (II), it is quite difficult to obtain uniform crystals. Since decomposition of II) takes place, it is usually 2-10 moles, preferably 2-6 moles. The reaction is usually carried out in the presence of water or an organic solvent or a mixed solvent thereof so as to proceed advantageously in terms of operability, yield, purification effect and the like. As the organic solvent used in the reaction, for example, ethanol, n-propanol, isopropanol, butanol, isobutanol, acetone, methyl ethyl ketone, acetonitrile, tetrahydrofuran, dioxane and the like (I) are poorly soluble and In addition to solvents that can be dissolved in water, these solvents and the target (I) are readily soluble and can also be dissolved in water, for example methanol, dimethyl sulfoxide, formamide, N, N-dimethylformamide, N, Mixed solvents with solvents such as N-dimethylacetamide, methyl cellulose solution, or these solvents and the target (I) are poorly soluble and difficult to dissolve in water, for example, ethyl acetate, ether, dichloro A mixed solvent with a solvent such as methane or chloroform is used. Among them, for example, a mixed solvent of water and acetone, ethanol, n-propanol, i-propanol, methyl ethyl ketone or tetrahydrofuran is very suitable. The reaction temperature is usually carried out in the temperature range of -10-40 ° C, preferably 0-30 ° C. Below -10 ℃, the crystal growth rate is slow and cooling is required during operation, and above 40 ℃, decomposition reaction of raw material (II) occurs, which is disadvantageous. The reaction time varies depending on the purity of the raw material (II) used and the type of impurities contained. However, when the raw material (II) having a purity of 80% or more purified by column chromatography using a conventional purification method such as an adsorbent or the like is used. It is 30 minutes-24 hours, Preferably it is 30 minutes-4 hours. Semi-product (I) is isolated by filtration or centrifugation, a freezing precursor, or the like. When the organic solvent is contained in the isolated compound (I), the organic solvent is removed and dried as necessary.

본 발명의 바람직한 실시양태를 들면,For a preferred embodiment of the present invention,

(가) 화합물(I)을 상기 용매에 용해시키고 계산량의 HX (X는 상기와 같다)를 첨가하며, 반응생성물을 동결건조시킨다. 이것을 다시 감압하에 실리카겔, 무수인산등 탈수제의 존재하에 건조하면 화합물(I)의 무수물이 얻어진다나.(A) Compound (I) is dissolved in the solvent, a calculated amount of HX (X is as described above) is added, and the reaction product is lyophilized. When this is dried again in the presence of a dehydrating agent such as silica gel and phosphoric anhydride under reduced pressure, anhydride of compound (I) is obtained.

(나) 화합물(II)를 물 혹은 물과 상기 친수성유기용매와의 혼합물에 용해시키고, HX를 첨가하고, 반응종료후 얻어지는 용액에 상기 목적물(I)이 용해되기 어려운 유기용매를 용액이 흐려지기 시작할 때까지 서서히 가하고, 그대로 한시간 내지 수시간 방치한 후 다시 목적물(I)이 용해되기 어려운 유기용매를 새로이 결정이 석출되지 않을 때까지 서서히 가하며. 석출된, 결정을 여과, 원심분리등의 수단에 의하여 채취한다.(B) The compound (II) is dissolved in water or a mixture of water and the hydrophilic organic solvent, HX is added, and the organic solvent is less likely to dissolve in the solution obtained after the reaction is completed. Slowly add until starting, then leave it for an hour or several hours as it is, and then slowly add an organic solvent, which is hard to dissolve again, until new crystals do not precipitate. The precipitated crystals are collected by means of filtration and centrifugation.

이와 같이 하여 얻어지는 결정은, 통상 3-4수화물일지만 소량의 유기용매를 부착한다. 이것에서 정출온도, 용매등의 조건에 따라 수화화의 정도가 다르지만 통상 3-10수화물이고, 때로는 소량의 유기용매를 함유하는 경우도 있다. 통상 유기 용매는 감압하에 건조하면 제거되지만, 용매에 따라서는 감압건조로는 제거되지 않는 경우도 있으며 이와 같은 유기용매를 제거하려면, 이 결정을 수증기와 접촉시켜서 화합물(I)의 무수물 1몰에 대하여 약 5-10배몰 정도까지 물을 흡수시키는 것이 좋다. 이와같이 물을 함유한 것을 감압 (약 0-20mmHg)으로 유지하면 물이 제거되어 6수화물, 5수화물, 4수화물, 3수화물의 결정이 순차로 얻어진다.The crystal thus obtained usually has a small amount of an organic solvent although it is usually 3-4 hydrate. Although the degree of hydration differs according to conditions, such as a crystallization temperature and a solvent, it is a 3-10 hydrate normally and may contain a small amount of organic solvents sometimes. Normally, the organic solvent is removed when dried under reduced pressure, but depending on the solvent, it may not be removed under reduced pressure drying. To remove such an organic solvent, this crystal is brought into contact with water vapor to about 1 mole of anhydride of compound (I). Absorb water up to 5-10 moles. When the water-containing one is kept under reduced pressure (about 0-20 mmHg), the water is removed, and crystals of hexahydrate, pentahydrate, tetrahydrate and trihydrate are obtained in sequence.

3수화물 결정을 다시 상기 감압하에 무수인산(酸)등 탈수제의 존재하에 방치하면 2수화물결정, 1수화물결정, 무수물이 순차로 얻어진다. 이 변화의 과정에 있어서, 분자화합물에서 제거된 1몰이하의 수분이 분자화합물에 부착되는 일도 있고, 상이한 수화물의 혼합물인 경우도 있다.When the trihydrate crystal is left again under the above reduced pressure in the presence of a dehydrating agent such as phosphoric anhydride, dihydrate crystal, monohydrate crystal, and anhydride are sequentially obtained. In the course of this change, less than one mole of water removed from the molecular compound may adhere to the molecular compound, or may be a mixture of different hydrates.

(다) 상기한 (가)의 동결건조품를 수증기와 접촉시키면 수증기가 흡수되며, 수화물로서 결정화하고 이것을 건조시킴으로써 4수화물, 3수화물, 2수화물, 1수화물, 무수물이 순차로 얻어진다.(C) When the above-mentioned lyophilized product is brought into contact with water vapor, water vapor is absorbed, crystallized as a hydrate and dried, thereby obtaining tetrahydrate, trihydrate, dihydrate, monohydrate, and anhydride sequentially.

이리하여 얻이진 목적물(I)의 결정은 원소분석, 적정등의 정량에 의하여 원료(II)1몰에 대하여 2몰의 HX를 가지고 있는 것이 확인되었고, 현미경, 편광현미경, X선 회절형태 등에 의하여 결정성인 것이 확인되는 외에 적외선 흡수스펙트럼에 있어서 비결정성분말과는 다른, 폭이 좁고 예리한 피이크를 볼수있다. 또, 목적물(I)에 함유되는 수분을 가열건조함에 따라 1몰이하로 감소시키면 X선 회절형태에 있어서 벌써 결정성을 소실하는 경우도 있으나, 그 경우에도 편광현미경에 있어서는 간섭색(결정성)이 관찰된다.Thus obtained crystal of target (I) was confirmed to have 2 moles of HX per 1 mole of raw material (II) by elemental analysis, titration, etc., and according to the microscope, polarizing microscope, X-ray diffraction pattern, etc. Besides being confirmed to be crystalline, a narrow and sharp peak different from the amorphous powder in the infrared absorption spectrum can be seen. In addition, if the moisture contained in the target (I) is reduced to 1 mol or less by heating to dryness, the crystallinity may already be lost in the X-ray diffraction pattern, but in this case, the interference color (crystallinity) may be Is observed.

본 발명의 목적물(I)은, 결정 또는 건조에 의하여 얻어지는 비결정성분말을 그대로 사용하든지, 혹은 무독성 알칼리 또는 알칼리염 예를 들면 탄산수소나트륨, 탄산나트륨, 인산삼나트륨 등과 병용하여서 소망의 pH,이온형 이온강도로 조정하여 주사용 또는 경구용의 제제로 사용하여도 좋다.The objective (I) of the present invention is a desired pH or ion type using an amorphous powder obtained by crystallization or drying as it is, or in combination with a non-toxic alkali or alkali salt such as sodium bicarbonate, sodium carbonate, trisodium phosphate, or the like. It may be adjusted to ionic strength and used as a preparation for injection or oral use.

예를들면 목적물(I)을 몰당량의 탄산나트륨 수용액에 용해한 액(이하 C액이라 칭함)은, 예를 들면 수술용기구, 병실,음료수등의 소독제등의 외용 살균제로서 사용할 수 있을 뿐만아니라, 예를들면 사람,생쥐,큰쥐, 개 등의 온혈동물에 대해서 그램양성군(예를 들면 스테필로코커스 아우레우스 등)이나 그램음성군(예를들면, 에쉐리키아콜라이, 클레브시엘라뉴모니아에, 프로테우스 불가리스, 프로테우스 몰가니등)에 기인되는 전염성 질환의 치료약으로서 근육내 주사 혹은 정맥내주사에 의하여 투여된다. 수술용구의 외용살균제로서 사용할 경우에는, 무수상태의 목적물(I)로 환산하여 100r/ml수용액을 제조하여 수술용기구에 산포하면되고, 사람 혹은 쥐의 에쉐리키아 콜라이 감염에 의한 요로(尿路)감염증에 대해서는 무수상태의 목적물(I)로 환산하여서 약 5-50mg/kg을 1일 3회로 나누어서 C용액을 정맥내 주사를 하면 된다.For example, a solution obtained by dissolving a target (I) in an aqueous solution of sodium carbonate (hereinafter referred to as C solution) can be used as an external disinfectant such as, for example, a disinfectant such as a surgical instrument, a hospital room, and a drinking water. For example, for warm-blooded animals such as humans, mice, large mice, and dogs, gram-positive groups (e.g., Staphylococcus aureus, etc.) and gram-negative groups (e.g., Escherichia coli, Klebsiella pneumoniae) , Proteus vulgaris, Proteus molani, etc.) is administered by intramuscular injection or intravenous injection. When used as an external disinfectant for surgical instruments, 100 r / ml aqueous solution can be prepared in the form of anhydrous target (I) and dispersed in surgical instruments, and urinary tract caused by human or rat Escherichia coli infection. For infectious diseases, C solution is administered intravenously by dividing about 5-50mg / kg three times a day in terms of anhydrous target (I).

[참고예 1]Reference Example 1

무수상태로 환산한 목적물(I)의 항균력(MIC) 및 독성Antimicrobial Activity (MIC) and Toxicity of Target (I) in Anhydrous State

(1) 항균스펙트럼(한천희석법)(1) Antibacterial Spectrum (Agar Dilution Method)

스테필로코커스 아우레우스 FDA 209p 0.39mcg/mlStaphylococcus aureus FDA 209p 0.39mcg / ml

스테필로코커스 아우레우스 1840 0.78mcg/mlStaphylococcus aureus 1840 0.78mcg / ml

에쉐리키아콜라이-NIHT JC-2 0.2mcg/mlEscherichia coli-NIHT JC-2 0.2mcg / ml

에쉐리키아콜라이 0-111 0.05mcg/mlEscherichia coli 0-111 0.05mcg / ml

에쉐리키아콜라이 T-7 1.56mcg/mlEscherichia coli T-7 1.56mcg / ml

클레브시엘라뉴모니아에 DT 0.1mcg/mlKlebsiella pneumoniae DT 0.1mcg / ml

프로테우스불가리스 IFO 3988 1.56mcg/mlProteus vulgaris IFO 3988 1.56mcg / ml

프로테우스몰가니 IFO 3848 0.39mcg/mlProteus molgari IFO 3848 0.39mcg / ml

(2) 급성독성 (쥐, 복강내투여)(2) Acute toxicity (rat, intraperitoneal administration)

CD50

Figure kpo00005
20g/kgCD50
Figure kpo00005
20g / kg

단, 급성독성은 목적물(I)과 탄산나트륨의 1:1 (몰)혼합물로 실험하였다. 또, 본발명의 목적화합물(I)은 아래식에 나타난 바와같은 호변이성화(tautomerization)에 의해서 호변이성체(tautomer)를 취할수 있다.However, acute toxicity was tested with a 1: 1 (mole) mixture of the target (I) and sodium carbonate. The target compound (I) of the present invention can also take tautomers by tautomerization as shown in the following formula.

Figure kpo00006
Figure kpo00006

이 종류의 화합물의 존재상황에 대해서는 여러가지로 검토되어 있고, 문헌에는 어떤경우에도 치아조린폼을 취하고 [아크타. 크리스탈로 그래피카(Acta Crystallographica 27권 326p (1971)], 별도의 경우에는 치아졸, 폼을 취한다고 [케미스트리. 앤드. 인더스트리(Chemistry and Industry), 1966판 1634p]되어 있다. 그렇지만 본 발명의 목적화합물(I)은 각종의 측정결과에 의하면 하기식으로 나타나는 것 같은 수소 결합의 기여에 의하여 치아조린. 폼이 안정화되어 치아조린. 폼을 우위로 취한다고 생각된다.The presence of this type of compound has been studied in various ways, and in the literature, in all cases, the tooth deodorant foam is used [Acta. Acta Crystallographica Vol. 27, 326p (1971), and in other cases, toothbrushes and foams are taken [Chemistry and Industry, 1966, 1634p. According to various measurement results, it is thought that dental zorine and foam are stabilized by the contribution of hydrogen bonds, which are represented by the following formulas, to take advantage of dental zorine and foam.

Figure kpo00007
Figure kpo00007

그러나 이 종류의 평형은 목적화합물(I)의 놓여진 제상황, 예를들면 용매의 액성, 용매의 극성, 온도등에 의하여 유동적으로 변화하는 일도 있을 수 있다.However, this kind of equilibrium may be changed fluidly depending on the defrosting situation of the target compound (I), for example, the liquidity of the solvent, the polarity of the solvent, and the temperature.

따라서 목적화합물(I)의 명명은 어느폼으로 하여도 좋으나 본 발명에서는 목적화합물(I)을 치아조린. 폼으로 명명한다.Therefore, the naming of the target compound (I) may be any form, but in the present invention, the target compound (I) is teemed. Name it as a form.

[실시예 1]Example 1

(1) 2-(N,N-디메틸아미노)에틸아민 400g에 에테르 2.4

Figure kpo00008
를 첨가냉각하고 2황화탄소 400g과 에테르 4.0
Figure kpo00009
의 혼합액을 18-23℃로 한시간 걸려서 적가하고, 또 동온도로 한시간 교반하여 석출되는 2-(N,N-디메틸아미노)에틸아민카르보디치오산의 결정을 여취(濾取)하여 건조시킨다.(1) ether 2.4 to 400 g of 2- (N, N-dimethylamino) ethylamine
Figure kpo00008
Cool and add 400 g of carbon disulfide and ether 4.0
Figure kpo00009
The mixed solution of was added dropwise at 18-23 ° C. over 1 hour, and the crystal of 2- (N, N-dimethylamino) ethylaminecarbodiic acid precipitated by stirring at the same temperature for 1 hour was filtered and dried.

산출량 695g, 수율 93.3%, 융점 156-157°Yield 695 g, yield 93.3%, melting point 156-157 °

이 결정에 물 4.4

Figure kpo00010
을 첨가하여 교반하면서 8-13℃로 IN-KOH 4.32
Figure kpo00011
을 30-40분간 적가하고, 또 0-5℃로 요도드화메틸 668g, 아세톤 6.68
Figure kpo00012
의 혼합액을 30-40분간 적가하고, 동온에서 30분간 교반하였다. 감압하에 아세톤을 유거(溜去) 한후 수층을 초산에틸 3
Figure kpo00013
, 2
Figure kpo00014
로 추출하고, 초산에틸층을 포화식염수 2
Figure kpo00015
로 세착하고, 망초(芒硝)로 건조후 농축시켜서 얻은 결정을 N-헥산 500ml를 첨가하여 재결정하고, S-메틸-[2-(N,N-디메틸아미노)] 에틸아민카르보디치오에이트 575g,수율 75.5%, 융점 61-62℃를 얻었다. 이 결정 520g에 에탄올 1.05
Figure kpo00016
, 아자이드화나트륨(NaN3)190g, 순수한 물 2.1
Figure kpo00017
을 첨가하고, 3시간 가열, 환열시켰다. S-메틸-[2-N,N-디메틸아미노)] 에틸아민카르보디치에이트의 결정 52g의 에탄올 100ml 용액을 더 첨가하여 한시간 환류시킨다. 20℃로 냉각하고 순수한 물 2,0
Figure kpo00018
을 첨가하여 질소기류중 농염산으로 pH 2-2.5로 하였다. 감압으로 에탄올을 유거하고 암버얼라이트(Amberlite) IR-120(H형)[토마 &허스사제]에 통과시켜서 순수한 물로 산성이 소실할 때까지 세척하였다. 5% 암모니아수의 용출하는 분획을 농축하고 정출한 1-[2-(N,N-디메틸아미노)에틸]-5-메르캅토-1H-테트라졸 350g을 얻었다. 수율 69.3%, 융점 218-219℃. NMR(D2O 중등몰의 NaHCO3를 첨가하여 측정, τ) : 5.33(2H,t,
Figure kpo00019
Water on this crystal 4.4
Figure kpo00010
IN-KOH 4.32 at 8-13 ° C. with stirring
Figure kpo00011
Was added dropwise for 30-40 minutes, and 668 g of methyl iodide and acetone 6.68 at 0-5 ° C.
Figure kpo00012
The mixture was added dropwise for 30-40 minutes, and stirred at the same temperature for 30 minutes. After distilling off acetone under reduced pressure, the aqueous layer was diluted with ethyl acetate 3
Figure kpo00013
, 2
Figure kpo00014
Extracted with ethyl acetate and saturated saline 2
Figure kpo00015
The resulting crystals were washed with brine, dried over agar, concentrated and recrystallized by addition of 500 ml of N-hexane, 575 g of S-methyl- [2- (N, N-dimethylamino)] ethylaminecarbodizioate, Yield 75.5% and the melting point 61-62 degreeC were obtained. Ethanol 1.05 in 520g of this crystal
Figure kpo00016
, Sodium azide (NaN 3 ) 190 g, pure water 2.1
Figure kpo00017
Was added and heated and refluxed for 3 hours. S-Methyl- [2-N, N-dimethylamino)] Ethylamine Carbodiciate A further 52 ml of ethanol 100g solution was added to reflux for one hour. Cool to 20 ℃ and pure water 2,0
Figure kpo00018
Was added to pH 2-2.5 with concentrated hydrochloric acid in a nitrogen stream. The ethanol was distilled off under reduced pressure and passed through Amberlite IR-120 (type H) (manufactured by Thomas & Hurs) and washed with pure water until acid disappeared. An eluted fraction of 5% aqueous ammonia was concentrated to obtain 350 g of 1- [2- (N, N-dimethylamino) ethyl] -5-mercapto-1H-tetrazole. Yield 69.3%, melting point 218-219 ° C. NMR (measured by addition of NaHCO 3 in medium mole of D 2 O, τ): 5.33 (2H, t,
Figure kpo00019

(2) 7β-[2-(2-아미노-4-치아조린-4-일) 아세트아미드]-3-아세틸옥시메틸-3-세펨-4-카르본산 206g을 물 2.6

Figure kpo00020
에 첨가, 교반하면서 (1)에서 얻은 1-[2-(N,N-디메틸아미노)에틸]-5-메르캅토-1H-테트라졸 86.5g 및 탄산수소나트륨 42g을 첨가하였다. 65℃에서 75분간 교반시킨후 10℃로 냉각시켰다. 5N-HCI 250ml을 첨가 pH2.0으로 만들어 생성된 불용물을 여취하고 수세하였다.(2) 206 g of 7β- [2- (2-amino-4-thiazolin-4-yl) acetamide] -3-acetyloxymethyl-3-cepem-4-carboxylic acid
Figure kpo00020
To the mixture was added 86.5 g of 1- [2- (N, N-dimethylamino) ethyl] -5-mercapto-1H-tetrazole obtained in (1) and 42 g of sodium hydrogencarbonate while stirring. After stirring for 75 minutes at 65 ℃ cooled to 10 ℃. 250 ml of 5N-HCI was added to pH 2.0 to filter the resulting insolubles and wash.

여액, 세액을 합해서 탄산수소나트륨으로 pH5.2로 하여 암버얼라이트 XAD-II(100-200mesh)10

Figure kpo00021
로 충진된 컬럼에 통과시켰다. 물60
Figure kpo00022
로 세정하고 20%메탄올을 이어서 40%메탄올로 용출시키고, 목적물을 함유한 분획 11
Figure kpo00023
를 5
Figure kpo00024
까지 농축하고, 염기성 알루미나(300mesh)300g으로 충진된 컬럼 및 압버얼라이트 IR-120(H형)100ml로 충진된 컬럼에 통과시키고 컬럼을 수세했다. 용출액, 세액을 합해서 농축하여 2
Figure kpo00025
로 하였다. 5℃로 냉각하고 활성탄 5g을 첨가 5분간 교반후 여과하여 활성탄을 제거하였다. 여액을 동결건조하고 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미드]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 51.2g을 얻었다.Combine filtrate and washings with sodium hydrogencarbonate to pH5.2 Amberlite XAD-II (100-200mesh) 10
Figure kpo00021
It was passed through a column packed with. Water60
Figure kpo00022
Washed with 20% methanol and then eluted with 40% methanol, fraction 11 containing the desired product.
Figure kpo00023
5
Figure kpo00024
The mixture was concentrated to and passed through a column filled with 300 g of basic alumina (300 mesh) and a column filled with 100 ml of Abverolite IR-120 (type H), and the column was washed with water. Concentrate the eluate and the tax solution together 2
Figure kpo00025
It was set as. After cooling to 5 ° C., 5 g of activated carbon was added and stirred for 5 minutes to remove activated carbon. The filtrate was lyophilized and 7β- [2- (2-imino-4-thiazolin-4-yl) acetamide] -3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetra 51.2 g of sol-5-yl] thiomethyl-3-cepem-4-carboxylic acid was obtained.

NMR(60MHz, D20중)τ:3.45(S, 치아조린 5-H)4.35(d,7-H) 4.88(d,6-H)5.0-6.7(m,5×CH2)6.95(S,2×CH3).NMR (at 60 MHz, D 2 0) τ: 3.45 (S, 5-H) chia 4.35 (d, 7-H) 4.88 (d, 6-H) 5.0-6.7 (m, 5 × CH 2 ) 6.95 ( S, 2 × CH 3 ).

(3) (2)의 방법으로 얻은 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미드]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산의 등결건조품 263g(본품의 고속액체크로마토그래피에 의한 측정순도는 무수물로 환산하여서 93%이었다)를 물 1.0

Figure kpo00026
로 용해하고, 아세톤 1.0
Figure kpo00027
이어서 12N-HCI 150ml을 첨가하였다.(3) 7β- [2- (2-imino-4-thiazolin-4-yl) acetamide] -3- [1- [2-N, N-dimethylamino) ethyl obtained by the method of (2) ] -1H-tetrazol-5-yl] thioacetic-3-cefe-4-carboxylic acid isocratic dried product (263 g (purity measured by high-performance liquid chromatography of this product was 93% in terms of anhydrous) of water 1.0)
Figure kpo00026
Dissolved in acetone 1.0
Figure kpo00027
Then 150 ml of 12N-HCI was added.

본 용액에 활성탄 20g을 첨가 5℃에서 10분간 교반한후, 활성탄을 여과시켜서 제외하고 여액에 아세톤 5

Figure kpo00028
를 첨가하고 10℃에서 한시간 교반한 후, 다시 2
Figure kpo00029
의 아세톤을 첨가한시간 교반하여 정출된 결정을 여취하고, 아세톤 500ml로 4회 세정한후 건조시켜서, 상기 카르본산 2염 산염결정 262g을 얻었다. (순도 환산수율 94%).Add 20 g of activated carbon to the solution, stir at 5 ° C. for 10 minutes, and filter out the activated carbon.
Figure kpo00028
Added and stirred at 10 ° C. for one hour, followed by 2
Figure kpo00029
The mixture was stirred for a while to add acetone, and the crystals crystallized were filtered off, washed four times with 500 ml of acetone, and dried to obtain 262 g of the carboxylic acid dihydrochloride crystal. (94% purity conversion).

IR(KBr)cm-1: 1770(β-lactam)IR (KBr) cm -1 : 1770 (β-lactam)

원소분석치(C18H23N9O4S3. 2HCI. H2O)Elemental analysis (C 18 H 23 N 9 O 4 S 3. 2HCI. H 2 O)

실측치 C : 34.87 H: 4.52 N : 20.01 S : 15.33 CI : 11.24Found C: 34.87 H: 4.52 N: 20.01 S: 15.33 CI: 11.24

계산치 C : 35.06 H : 4.47 N: 20.45 S : 15.60 CI : 11.50Calculated C: 35.06 H: 4.47 N: 20.45 S: 15.60 CI: 11.50

칼핏샤법에 의한 수분 : 실측치 3.15%Moisture by the Cal Fitsha method: found 3.15%

계산치 2.92%Calculated 2.92%

NMR(60MHz,D20중)τ:3.20(S, 치아조린 5-H)4.25(d,7-H)4.75(d,6-H)4.9-6.5(m, 5×CH2)6.85(S,2×CH3).NMR (at 60 MHz, D 2 0) τ: 3.20 (S, 5-H) 4.25 (d, 7-H) 4.75 (d, 6-H) 4.9-6.5 (m, 5 × CH 2 ) 6.85 ( S, 2 × CH 3 ).

본품의 고속액체크로마토그래피에 의한측정순도는 무수물로 환산하여서 99.6%이고 X선회절 형태는 본품이 결정인 것을 나타냈다. 액체크로마토그래피의 조건 :The purity of the product by high-performance liquid chromatography was 99.6% in terms of anhydride, and the X-ray diffraction pattern indicated that the product was a crystal. Conditions for Liquid Chromatography:

분리관 : 히다찌 이온교환수지 2614, 21mm×50cm, 분리관 온도 : 50℃, 용리액 : 0.3M 구연산완충액, pH6.5, 0.2ml/min, 압력 : 4.3kg/cm2기록계감도 : 10mv, 기록지속도 : 2.5mm/min.Separation tube: Hitachi ion exchange resin 2614, 21mm × 50cm, Separation tube temperature: 50 ℃, Eluent: 0.3M citric acid buffer solution, pH6.5, 0.2ml / min, Pressure: 4.3kg / cm 2 Recorder sensitivity: 10mv, Recording speed : 2.5 mm / min.

(4) (3)에서 얻은 결정 10g을 35℃로 무수인산의 존재하에 진공도 2mmHg로 3시간 진공건조시키고, 상기 카르본산이염산염분말 9.8g을 얻었다. 칼핏샤법에 의한 수분측정치 1.9%, 본품은 X선 분말회절형태에서는 비결정성의 분말이었다. 편광현미경에 의한 관찰로는 직교니콜을 사용하여서 재물대를 회전하면 간섭색을 나타내고 광학적으로 이방(異方)이고, 결정성을 나타냈다.(4) 10 g of the crystal obtained in (3) was vacuum dried at 35 deg. C in the presence of phosphoric anhydride at a vacuum degree of 2 mmHg for 3 hours to obtain 9.8 g of the carboxylic acid dihydrochloride powder. The moisture measurement value 1.9% by the Karl Fischer method and this product were amorphous powder in the X-ray powder diffraction pattern. Observation by a polarizing microscope showed the interference color, optically anisotropy, and crystallinity when the material stage was rotated using orthogonal Nicole.

(5) (3)에서 얻은 결정 20g을 물 200ℓ에 용해시키고, 10℃로 냉각시키고, 암버얼라이트 IR-45(OH형) 135ml로 충전된 컬럼에 30분간 통과시키고 300ml의 물로 세척하였다. 유출액을 동결건조하여 16.0g의 7β-[2-(2-아미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산을 얻었다. 본품의 칼핏샤법에 의한 수분은 3.20%이고 고속액체크로마토그래피에 의해 정량된 무수물 환산순도는 99.2%이었다.(5) 20 g of the crystal obtained in (3) was dissolved in 200 L of water, cooled to 10 DEG C, passed through a column filled with 135 ml of Amberlite IR-45 (type OH) for 30 minutes and washed with 300 ml of water. The effluent was lyophilized to give 16.0 g of 7β- [2- (2-amino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl]- 1H-tetrazol-5-yl] thiomethyl-3-cepem-4-carboxylic acid was obtained. The moisture by the Kalpitsha method of this product was 3.20%, and the purity of the anhydride converted by high-performance liquid chromatography was 99.2%.

[실시예 2]Example 2

7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 10g을 물 30ml에 용해하고, 5℃에서 교반하면서 메틸에틸케톤 150ml 및 12N-HCl5.5ml을 첨가하였다. 3시간 교반한 후 5℃로 하루밤 방치하고 정출된 결정을 여취하여, 메틸에틸케톤 20ml로 4회 세정한 후 건조하고, 표제 카르본산의 이염산염 결정 10.5g을 얻었다.7β- [2- (2-imino-4-thiazolin-4-yl) acetamido-3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol-5-yl ] 10 g of thimethyl-3-cepem-4-carboxylic acid was dissolved in 30 ml of water, and 150 ml of methylethylketone and 5.5 ml of 12N-HCl were added with stirring at 5 ° C. After stirring for 3 hours, the mixture was left overnight at 5 ° C., and the crystals thus obtained were filtered off, washed four times with 20 ml of methyl ethyl ketone, and dried to obtain 10.5 g of dihydrochloride crystals of the title carboxylic acid.

원소분석치(C18H23N9O4S3. 2HCI. 2H2O)Elemental analysis (C 18 H 23 N 9 O 4 S 3. 2HCI. 2H 2 O)

실측치 C : 33.94 H: 4.80 N : 20.02 CI : 11.15Found C: 33.94 H: 4.80 N: 20.02 CI: 11.15

계산치 C : 34.07 H : 4.61 N: 19.86 CI : 11.17Calculated C: 34.07 H: 4.61 N: 19.86 CI: 11.17

칼핏샤법에 의한 수분 : 측정치 5.80%Moisture by the Calfitsha method: measured value 5.80%

계산치 5.68%Calculated 5.68%

[실시예 3]Example 3

7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 0.53g을 물 1.5ml에 용해하고, 5℃에서 5N-HBr수용액 0.7ml을 첨가하였다.7β- [2- (2-imino-4-thiazolin-4-yl) acetamido-3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol-5-yl ] 0.53 g of thimethyl-3-cepem-4-carboxylic acid was dissolved in 1.5 ml of water, and 0.7 ml of 5N-HBr aqueous solution was added at 5 ° C.

이 액에 아세톤 11ml를 첨가하고, 10℃에서 두시간 교반한 후 다시 아세톤 5ml을 첨가하여 25℃에서 한시간 교반하였다. 정출한 결정을 여취하고, 아세톤 2ml로 5회 세정하여서 대기중에서 건조시킨후 진공건조에 의하여 표제 카르본산의 2취화수소산염 결정 0.56g을 얻었다.11 ml of acetone was added to this solution, the mixture was stirred at 10 ° C. for 2 hours, 5 ml of acetone was further added, and the mixture was stirred at 25 ° C. for 1 hour. The crystals thus obtained were filtered off, washed 5 times with 2 ml of acetone, dried in air, and dried under vacuum to obtain 0.56 g of dihydrogen hydrochloride crystals of the title carboxylic acid.

NMR(60MHz,D20중)τ:3.22(S,치아조린 5-H)4.26(d,7-H)4.75(d,6-H)4,9-6.5(m,5×CH2)6.88(S,2×CH3)NMR (in 60 MHz, D 2 0) τ: 3.22 (S, Chiazoline 5-H) 4.26 (d, 7-H) 4.75 (d, 6-H) 4, 9-6.5 (m, 5 × CH 2 ) 6.88 (S, 2 × CH 3 )

본품은 X선 분말회절형태 및 편광현미경 관찰의 결과결정성이란 것이 확인되었다.It was confirmed that this product was crystallinity as a result of X-ray powder diffraction pattern and polarization microscope observation.

[실시예 4]Example 4

(1) 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 의 동결 건조품 5.26g(본품은 칼핏샤법으로 측정된 수분치가 3.2%이고 고속액체 크로마토그래피로 측정한 쌍성 이온함량이 95.5%이었다)을 물 50ml에 용해하고 5℃로 냉각하며 1N-HCI 18.7ml을 첨가하고 동결 건조하여 상기 카르본산. 2HCI.1.5H2O의 분말 6.2g을 얻었다.(1) 7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazole 5.26 g of a freeze-dried product of -5-yl] thiomethyl-3-cepem-4-carboxylic acid (this product had a water content of 3.2% as measured by the Karl Fischer method and a binary ion content of 95.5% as determined by high performance liquid chromatography). The carboxylic acid was dissolved in 50 ml of water, cooled to 5 ° C., 18.7 ml of 1N-HCI, and lyophilized. 6.2 g of a powder of 2HCI.1.5H 2 O was obtained.

수분함량 : (칼핏샤법) 4.2% (C18H23N9O4S3.2HCI.1.5H2O의 계산치 4.3%)Moisture content: (Kalfitsha method) 4.2% (calculated 4.3% of C 18 H 23 N 9 O 4 S 3 .2HCI.1.5H 2 O)

원소분석치(C18H23N9O4S3.2HCI.1.5H2O)Elemental Analysis Value (C 18 H 23 N 9 O 4 S 3 .2HCI.1.5H 2 O)

실측치 C :34.21 H: 4.03 N : 19.82 CI : 11.50Found C: 34.21 H: 4.03 N: 19.82 CI: 11.50

계산치 C : 34.56 H : 4.19 N: 20.15 CI : 11.33Calculated C: 34.56 H: 4.19 N: 20.15 CI: 11.33

순도 : 95.3%(고속액체크로마토그래피로 정량하여 2HCI 염무수물로 환산하였다)Purity: 95.3% (quantified by high performance liquid chromatography, converted into 2HCI brine)

X선분말도형 : 비결정성X-ray powder shape: amorphous

편광현미경에 의한 관찰 : 직교니콜을 사용하여 재물대를 회전하여도 간섭색을 나타내지 않고 비결정형이었다.Observation by the polarizing microscope: Even when the material band was rotated using orthogonal nicotine, it was amorphous without exhibiting interference colors.

(2) (1)에서 얻은 분말 2g을 실리카겔을 넣은 데시케이터 중에서 진공건조시켜 상기 카르본산. 2HCI.0.17 H2O의 분말 1.9g을 얻었다.(2) The carboxylic acid was dried by vacuum drying 2 g of the powder obtained in (1) in a desiccator containing silica gel. 1.9 g of 2 HCI.0.17 H 2 O powder was obtained.

수분함량(칼핏샤법) 0.5%(C18H23N9O4S3.2HCI 0.17 H2O의 계산치 0.5%), 순도95.3%(고속액체크로마토그래피로 정량하고 2염산염무수물로 환산하였다), X선분말회절형태 비결정성, 편광현미경 관찰 : 간섭색을 나타내지 않았다.Moisture content (kalpit syabeop) 0.5% (C 18 H 23 N 9 O 4 S 3 .2HCI 0.17 Calcd 0.5% of H 2 O), purity 95.3% (quantified by high performance liquid chromatography and was converted to the dihydrochloride anhydride), X-ray powder diffraction pattern Amorphous, polarization microscope observation: No interference color.

(3) (1)에서 얻은 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산. 2염산염의 동결건조품 1g에 순수한 물 0.5g을 첨가하여 용해하고, 5℃에서 15시간 정치한 후 무수인산을 넣은 데시 케이터중에서 건조하여 상기 카르본산의 2염산염 결정 1.05g을 얻었다.(3) 7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl] obtained in (1). -1H-tetrazol-5-yl] thiomethyl-3-cepem-4-carboxylic acid. 0.5 g of pure water was added to 1 g of the lyophilized product of dihydrochloride, dissolved for 15 hours at 5 ° C, and dried in a desiccator containing phosphoric anhydride to obtain 1.05 g of the dihydrochloride crystal of carboxylic acid.

원소분석치(C18H23N9O4S3.2HCI-2H2O)Elemental Analysis Value (C 18 H 23 N 9 O 4 S 3 .2HCI-2H 2 O)

실측치 C : 33.84 H: 4.64 N : 19.71 S : 15.40 CI : 11.29Found C: 33.84 H: 4.64 N: 19.71 S: 15.40 CI: 11.29

계산치 C : 34.07 H : 4.61 N: 19.86 S : 15.16 CI : 11.17Calculated C: 34.07 H: 4.61 N: 19.86 S: 15.16 CI: 11.17

칼핏샤법에 의한 수분측정치 : 6.00%(계산치 5.68%)Moisture measurement by Kalpitsha method: 6.00% (calculated 5.68%)

IR(KBr)cm- 1: 1770(β-lactam), 결정에 특유한 폭이 좁고 예리한 흡수가 1670,1190,1170에 보였다. IR (KBr) cm - 1: 1770 (β-lactam), a distinctive narrow and sharp absorption in the crystal is shown in 1670,1190,1170.

[실시예 5]Example 5

무수물로 환산한 순도가 93%인 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산의 동결건조품 5.5g을 물 25ml에 용해하고, 아세톤 25ml을 첨가한 후 12N-HCI 4ml을 첨가하고 아세톤을 또 100ml 첨가한후 15℃에서 한시간 동안 교반하였다. 다시 아세톤 50ml을 첨가하고 한시간 교반한 후 여취하여, 아세톤 10ml로 4회 세척하였다. 건조에 의해 상기 카르본산의 2염산염 결정 5.55g을 얻었다.7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl with 93% purity in terms of anhydride ] 5.5 g of a freeze-dried product of] -1H-tetrazol-5-yl] thiomethyl-3-cepem-4-carboxylic acid was dissolved in 25 ml of water, 25 ml of acetone was added, then 4 ml of 12N-HCI was added, and acetone was further added. After adding 100ml, the mixture was stirred at 15 ° C for one hour. Again 50 ml of acetone were added, stirred for one hour, filtered, and washed four times with 10 ml of acetone. 5.55 g of dihydrochloride crystals of the carboxylic acid were obtained by drying.

(순도환산수율 92%)(92% purity conversion)

원소분석치(C18H23N9O4S. 2HCI. H2O)Elemental Analysis Value (C 18 H 23 N 9 O 4 S. 2HCI. H 2 O)

실측치 C : 34.48 H: 4.48 N : 20.55 S : 15.22 CI : 11.49Found C: 34.48 H: 4.48 N: 20.55 S: 15.22 CI: 11.49

계산치 C : 35.06 H : 4.41 N: 20.45 S : 15.60 CI : 11.50Calculated C: 35.06 H: 4.41 N: 20.45 S: 15.60 CI: 11.50

본품은 X선 분말회절형태에 있어서 결정성 분말인 것으로 나타나고, 고속액체크로마토그래피에 의해 측정한 무수물 환산순도는 99.4%이었다.This product appeared to be a crystalline powder in X-ray powder diffraction form, and the purity of anhydride measured by high performance liquid chromatography was 99.4%.

[실시예 6]Example 6

7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 이염산염의 동결 건조품 6.2g에 2N-HCI 19ml를 첨가하여 용해하고 이 액을 에탄올 250ml와 5℃에서 교반하면서 2시간 걸려서 혼합하였다. 또 10℃에서 2시간동안 교반한 후 침전물을 여취하여, 에탄올 15ml로 4회 세척하고 대기중에서 건조시킨후 30℃에서 감압 건조시켜서, 상기 카르본산 2염산염 결정 5.6g을 얻었다.7β- [2- (2-imino-4-thiazolin-4-yl) acetamido-3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol-5-yl ] 19 g of 2N-HCI was added to 6.2 g of a freeze-dried product of thimethyl-3-cepem-4-carboxylic acid dihydrochloride, and the mixture was mixed for 2 hours with 250 ml of ethanol and stirring at 5 ° C. After stirring at 10 ° C. for 2 hours, the precipitate was filtered off, washed four times with 15 ml of ethanol, dried in air, and dried under reduced pressure at 30 ° C. to obtain 5.6 g of the carboxylic acid dihydrochloride crystal.

본품은 X선 분말회절법 및 편광현미경 관찰의 결과 결정성인 것이 확인되었다.This product was confirmed to be crystalline as a result of X-ray powder diffraction and polarization microscope observation.

[실시예 7]Example 7

7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 510g을 함유하는 pH 2.0의 수용액 5.0

Figure kpo00030
를 10℃로 생각하고 활성탄 7.0g을 첨가하여 5분간 교반한 후 활성탄을 여과하여 제거하고 활성탄을 500ml의 물로 세척한 후 여액, 세액을 합하여서 2.38
Figure kpo00031
까지 감압하에 내온 15-17℃에서 농축하고 또 다시 여과세척했다. 여과액 및 세척액은 2.38ℓ이며 상기 카르본산 478g을 함유하고 있었다. 여액에 아세톤 0.2
Figure kpo00032
를 첨가하고 이어서 12N-HCI 170ml을 첨가했다. 다시 7
Figure kpo00033
의 아세톤을 10분간 걸려서 첨가하고, 5-10℃에서 두시간 교반한 후 또 다시 아세톤 7
Figure kpo00034
를 30분 걸려서 첨가하였다. 또 한시간 교반한 후 하룻밤 정치하여 정출된 결정을 여취하고 아세톤 1
Figure kpo00035
로 4회 세척하였다. 본 결정(결정의 일부를 취하여 데시케이터중에서 30분간 실온, 진공도 30mmHg의 조건으로 건조시킨 것은 칼핏샤법에 의하여 측정한 수분함량이 8.9%이고 아세톤 2.2%가 부착되어 있었다. C18H23N9O4S3-2HCI-3H2O의 수분의 계산치는 8.28%)을 다른 유리필터에 옮겨서 물을 넣은 병에 통과시켜 가습시킨(수온은 25-30℃로 유지함)질소가스를 8
Figure kpo00036
/min의 속도로 6시간 결정층에 통과시켰다. 이 결정 (결정의 일부를 취하여 칼핏샤법에 의하여 측정한 수분은 19.5%였다. C18H23N9O4S3.2HCI·8H2O의 수분의 계산치는 19.41%, 본품은 아세톤을 전혀 함유하고 있지않고 X선 분말회절형태는 결정성을 나타냈다)을 약 3cm의 두께로 넓히고 30℃에서 5mmHg의 진공도를 1.5시간 건조시켰다.(이것을 일부 취하여 칼핏샤법으로 측정한 수분은 17.2%이었다. C18H23N9O4S3.2HCI. 7H2O의 수분의 계산치는 17.41%) 또 같은 조건에서 1.5시간 건조시키고( 칼핏샤법에 의한 수분 15.4%) C18H23N9O4S3.2HCI. 6H2O로서의 수분의 계산치는 15.3%) 또 1.5시간 건조시키고(칼핏샤법에 의한 수분 13.3%C18H23N9O4S3·2HCI·5H2O의 계산치는 13.08%) 또 1.5시간 건조시키고 (칼핏샤법에 의한 수분 10.5% C18H23N9O4S3·2HCI·4H2O의 계산치는 10.75%)또 1.5시간 건조하여 525g의 결정을 얻었다.7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol-5- Aqueous solution of pH 2.0 containing 510 g of thimethyl-3-cepem-4-carboxylic acid.
Figure kpo00030
Is considered to be 10 ℃, add 7.0g of activated carbon, stir for 5 minutes, filter out activated carbon, wash activated carbon with 500ml of water, add filtrate and tax solution, and add 2.38.
Figure kpo00031
The mixture was concentrated under reduced pressure at 15-17 ° C. under reduced pressure and filtered again. The filtrate and wash were 2.38 L and contained 478 g of the carboxylic acid. Acetone 0.2 in the filtrate
Figure kpo00032
Was added followed by 170 ml of 12N-HCI. 7 again
Figure kpo00033
Acetone was added over 10 minutes, stirred at 5-10 ° C. for 2 hours, and then again with acetone 7
Figure kpo00034
Was added over 30 minutes. After stirring for another hour, it was allowed to stand overnight to filter out the crystallized acetone 1
Figure kpo00035
Washed 4 times. The crystals (part of the crystals were dried in a desiccator for 30 minutes at room temperature and a vacuum degree of 30 mmHg) had a water content of 8.9% and acetone 2.2% as measured by the Kalfitsha method. C 18 H 23 N 9 The calculated water content of O 4 S 3 -2HCI-3H 2 O is 8.28%), transferred to another glass filter, and passed through a bottle filled with water to humidify (keep water temperature at 25-30 ℃).
Figure kpo00036
Passed through the crystal layer for 6 hours at a rate of / min. This crystal (Moisture measured by Kalfitsha method with a part of crystal was 19.5%. C 18 H 23 N 9 O 4 S 3. The calculated value of water of 2HCI · 8H 2 O was 19.41%, and the product contained no acetone. The X-ray powder diffraction pattern showed crystallinity) to a thickness of about 3 cm and dried at a vacuum degree of 5 mmHg at 30 ° C. for 1.5 hours (partially taken and measured by Kalpitsha method was 17.2%. C 18 H 23 N 9 O 4 S 3. 2HCI. calculated values of 17.41% of water 7H 2 O) and 1.5 hours again dried under the same conditions (15.4% moisture by kalpit syabeop) C 18 H 23 N 9 O 4 S 3. 2HCI. The calculated value of water as 6H 2 O was 15.3%) and dried for another 1.5 hours (the calculated value of 13.3% C 18 H 23 N 9 O 4 S 3 · 2HCI · 5H 2 O by Calpissha method was 13.08%) and dried for 1.5 hours. (Calculated value of water 10.5% C 18 H 23 N 9 O 4 S 3 .2HCI.4H 2 O by Kalpitsha method was 10.75%) and dried for 1.5 hours to obtain 525 g of crystals.

수분함량 (칼핏샤법) : 8.50% (C18H23N9O4S3·2HCI·3H2O로서의 계산치는 8.28%, X선 분말회절형태 : 결정성을 나타냈다. CI함량(AgNO3적정법) : 10.6% (C18H23N9O4. 2HCI. 3H2O의 계산치 10.8%).Moisture content (Kalfitsha method): 8.50% (Calculated as C 18 H 23 N 9 O 4 S 3 · 2HCI · 3H 2 O, 8.28%, X-ray powder diffraction type: Crystallinity. CI content (AgNO 3 titration method) : 10.6% (calculated for C 18 H 23 N 9 O 4 .2HCI. 3H 2 O 10.8%).

(2) (1)에서 얻은 결정을 30℃에서 2mmHg의 진공도로 무수인산의 존재하에 5시간건조시켜 510g의 결정을 얻었다. 수분함량(칼핏샤법) : 5.7% (C18H23N9O4S3.2HCI. 2H2O의 계산치 5.68%) : X선분말회절형태 : 결정성을 나타냈다. IR(KBr)cm-1: 1770(β-lactan),결정에 특유한 날카로운 피이크가 1670, 1190(sh.), 1170에 나타남.(2) The crystals obtained in (1) were dried at 30 DEG C in a vacuum of 2 mmHg in the presence of phosphoric anhydride for 5 hours to obtain 510 g of crystals. Moisture content (Kalfitsha method): 5.7% (calculated C 18 H 23 N 9 O 4 S 3. 2HCI. 2H 2 O 5.68%): X-ray powder diffraction Form: Crystallinity. IR (KBr) cm -1 : 1770 (β-lactan), sharp peaks peculiar to crystallization appear at 1670, 1190 (sh.), 1170.

(3) (2)에서 얻은 결정을 30℃에서 2mmHg의 진공도로 무수인산의 존재하에 8시간 건조하고 495g의 결정을 얻었다. 수분함량(칼핏샤법) : 3.12% (C18H23N9O4S3.2HCI. H2O의 계산치 2.92% : 무수물로 환산한 순도(고속액체 크로마토그래피로 측정하여 2염산염 무수물로 환산했다) : 99.5%, X선분말회절 형태 : 결정성을 나타냈다.(3) The crystals obtained in (2) were dried at 30 ° C. in a vacuum of 2 mmHg in the presence of phosphoric anhydride for 8 hours to obtain 495 g of crystals. Moisture content (Kalfitsha method): 3.12% (C 18 H 23 N 9 O 4 S 3. 2HCI.H 2 O calculated value 2.92%: Purity in terms of anhydrous (measured by high-performance liquid chromatography in terms of dihydrochloride anhydride). ): 99.5%, X-ray powder diffraction form: Crystallinity was shown.

원소분석치(C18H23N9O4S3. 2HCI. H2O)Elemental analysis (C 18 H 23 N 9 O 4 S 3. 2HCI. H 2 O)

실측치 C : 34.78 H: 4.51 N : 20.62 S : 15.31 CI : 11.77Found C: 34.78 H: 4.51 N: 20.62 S: 15.31 CI: 11.77

계산치 C : 35.06 H : 4.41 N: 20.45 S : 15.60 CI : 11.50Calculated C: 35.06 H: 4.41 N: 20.45 S: 15.60 CI: 11.50

Figure kpo00037
(C=1%, H2O)=+67.0°; 잔존용매(아세톤) : 50ppm 이하, CI함량(AgNO3적정법) : 11.4%, 이론치 11.50 ; λmax (H2O) : 258mμ(ε19.500) ; 생물학적역가 865mcg/ml
Figure kpo00037
(C = 1%, H 2 O) = + 67.0 °; Residual solvent (acetone): 50 ppm or less, CI content (AgNO 3 titration method): 11.4%, theoretical value 11.50; λ max (H 2 O): 258 mμ (ε 19.500); Biological titer 865mcg / ml

생물학적역가는7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 2HCI염을 표준품으로 사용하며 시험균으로서 B. Subtilis ATCC 6633을 사용하여 컵법에 의하여 측정하였다.The biological titer is 7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazole -5-yl] thiomethyl-3-cepem-4-carboxylic acid 2HCI salt was used as a standard and measured by the cup method using B. Subtilis ATCC 6633 as a test bacterium.

무수양성 이온화합물의 역가는 1000mcg/ml이고, 양성이온화합물 1몰에 대하여 2몰의 염산을 함유하고 다른 비결합성 염산, 수분, 잔존용매등의 불순물을 함유하지 않은 시료의 계산상의 역가는 878mcg/ml 일것이다.The anhydrous positive ion compound has a titer of 1000 mcg / ml and a calculated titer of 878 mcg / ml for a sample containing 2 moles of hydrochloric acid per mole of the zwitterionic compound and no impurities such as other non-binding hydrochloric acid, water, and residual solvent. will be ml.

[실시예 8]Example 8

(1) 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산의 동결건조품 5.26g (본품은 칼핏샤법으로 측정한 수분치가 3.1%이고 고속액체크로마토그래피로 측정한 쌍성 이온체 함량은 93.5%이었다)을 물 20cc에 첨가 용해하였다. 이 용액에 아세톤을 20ml이어서 10N-HCI 4ml를 첨가하였다. 아세톤 96ml를 20℃에서 교반하면서 10분간 첨가하여 2시간 교반한 후 다시 72ml의 아세톤을 20분 동안 첨가하고 종료후 30분 교반하여 생긴 결정을 여취하고 아세톤 15ml로 5회 세척한 결정을 상대습도 58%의 습기있는 공기에서 2시간 대기중에서 건조시키고 습기 있는 결정 6.0g을 얻었다(본품은 칼핏샤법으로 측정한 수분치가 13%였다. 본품을 감압하에 2시간 건조시켜 상기 카르본산 2HCI. 4H2O 결정 5.7g을 얻었다.(1) 7β- [2- (2-imino-4-thiazolin-4-yl) acetamido-3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol- 5.26 g of a freeze-dried product of 5-yl] thiomethyl-3-cepem-4-carboxylic acid (this product had a moisture content of 3.1% measured by the Calpissha method and a binary ion content of 93.5% measured by high performance liquid chromatography). Dissolve in addition to 20 cc of water. To this solution was added 20 ml of acetone and 4 ml of 10N-HCI. 96 ml of acetone was added for 10 minutes with stirring at 20 ° C., followed by stirring for 2 hours, followed by addition of 72 ml of acetone for 20 minutes, followed by stirring for 30 minutes. The crystals were washed five times with 15 ml of acetone. It dried in air | atmosphere for 2 hours in% humid air, and obtained 6.0 g of wet crystals (this product measured the moisture value by 13% by the Calpissha method. The product was dried under reduced pressure for 2 hours, and the said carboxylic acid 2HCI. 4H 2 O crystal was obtained. 5.7 g was obtained.

수분함량 : (칼핏샤법) 10.9% (C18H23N9O4S3.2HCI. 0.1H2O의 계산치 0.3%), X선분말회절형태 : 비결정형을 나타냈다. 편광현미경에 관한 관찰 : 직교니콜을 사용하며 재물대를 회전시키면 간섭색을 나타내며 광학적으로 이방이고 결정성을 나타냈다. 순도 : 99.6%(고속액체크로마토그래피로 정량하며 2염산염무수물로 환산하였다).Water content: (Kalfitsha method) 10.9% (calculated for C 18 H 23 N 9 O 4 S 3. 2HCI. 0.1H 2 O 0.3%), X-ray powder diffraction form: Amorphous. Observation on the polarizing microscope: Orthogonal Nicole was used, and when rotating the stage, it showed interference color, optically anisotropic and crystallinity. Purity: 99.6% (quantified by high performance liquid chromatography, and converted into dihydrochloride anhydrous).

[실시예 9]Example 9

(1)7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산을 함유하는 수용액 5ml(이 용액은 고속액체 크로마토그래피에 의한 정량의 결과 10.05g의 상기카르본산 및 15mg. 1-[2-(N,N-디메틸아미노)에틸]-5-메르캅토-1H-테트라졸 및 기타의 미량불순물을 함유하고 있었다)에 4N-HCI 1.0ml을 첨가하여 이 액을 5℃로 냉각시킨 아세톤 300ml중에 교반하면서 조금씩 적가하였다. 분말화된 침전을 여취하고 아세톤 5ml로 4회 세척하고 감압하에 건조시켜 상기 카르본산. 2HCI.1.2H2O 분말 1.2g을 얻었다.(1) 7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazole 5 ml of aqueous solution containing -5-yl] thiomethyl-3-cepem-4-carboxylic acid (this solution is 10.05 g of the carboxylic acid and 15 mg. 1- [2- (N as a result of quantification by high performance liquid chromatography). (N-dimethylamino) ethyl] -5-mercapto-1H-tetrazole and other trace impurities) was added 1.0 ml of 4N-HCI and the solution was stirred in 300 ml of acetone cooled to 5 ° C. Little by little The powdered precipitate was filtered off, washed four times with 5 ml of acetone and dried under reduced pressure to give the carboxylic acid. 1.2 g of 2HCI.1.2H 2 O powder was obtained.

수분함량 : (칼핏샤법) 3.45% (C18H23N9O4S3·2HCI·1.2H2O의 계산치 3.48%), CI함량 : (AgNO2적정법 11.6%( C18H23N9O4S3·2HCI·1.2H2O의 계산치 11.4%)순도 : 96.2%(고속액체 크로마토그래피로 측정하고 2염산염 무수물로 환산함) X선 분말회절형태 : 비결정형.Moisture content: (Kalfitsha method) 3.45% (calculated C 18 H 23 N 9 O 4 S 3 · 2HCI · 1.2H 2 O 3.48%), CI content: (AgNO 2 titration method 11.6% (C 18 H 23 N 9 O 4 S 3 · 2HCI · calculated 11.4% of 1.2H 2 O) purity: 96.2% (also in terms of high performance liquid chromatography to measure the dihydrochloride anhydride) X-ray powder diffraction pattern: amorphous.

(2) (1)에서 얻은 분말 0.3g을 샤아레에 펴서 포화 NaBr 수용액을 넣은 데시케이터중에서 25℃로 하룻밤동안 흡습시켰다. 분말은 일단 흡습하여 기름상이 된후, 고화된다.(2) 0.3 g of the powder obtained in (1) was spread over a charare and absorbed overnight at 25 ° C. in a desiccator containing a saturated aqueous NaBr solution. The powder is once hygroscopic and becomes oily and then solidifies.

이것을 감압건조시키고 상기 카르본산. 2HCI. 2.3H2O 결정 0.3g을 얻었다.It was dried under reduced pressure and the carboxylic acid. 2HCI. 0.3 g of 2.3H 2 O crystals were obtained.

수분함량 : (칼핏샤법) 6.6% (C18H23N9O4S3.2HCI. 2.3H2O의 계산치 6.5%)Moisture content: (Kalfitsha method) 6.6% (calculated C 18 H 23 N 9 O 4 S 3. 2HCI. 2.3H 2 O 6.5%)

순도 : 95.2%, CI함량 : 원소분석치 11.5%(계산치 11.1%) X선 분말회절형태 : 결정성을 나타냈다.Purity: 95.2%, CI Content: Elemental Analysis 11.5% (Calculated 11.1%) X-ray powder diffraction Form: Crystallinity.

[실시예 10]Example 10

(1) 7-아미도-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 42.4g 을 디클로로메탄 1.1

Figure kpo00038
에 첨가하고 -10℃에서 교반하면서 디사이클로헥실아민 59.8g을 5분간 걸려서 첨가하였다. 20분후 4-클로로-3-옥소-브티릴클로리드의 디클로로메탄용액 (1.4mol/kg)154g을 35분간 걸려서 첨가하였다. 35분후 또 22g을 추가하여 20분간 교반하였다. 이 용액에 물 300ml 및 5N-HCI 20ml을 첨가하여 25℃에서 30분 교반한 후 여과하고 수세하였다. 본 여과액 및 세척액을 디클로로메탄으로 세척하고 디콜로로메탄층을 물로 추출한 후 합친 수층에 치오우레아 12.5g을 첨가하고, 탄산수소나트륨으로 pH 5.0로 만들고 실온에서 3시간 방치한 후 10℃에서 하루밤 방치하고 탄산수소나트륨으로 pH 5.2로 만들었다. 이 액을 암버얼라이트 XAD-2 (100-200mesh) 2.5
Figure kpo00039
로 충전된 컬럼에 통과시키고 7.5
Figure kpo00040
의 물로 세척한 후 15%메탄올 4
Figure kpo00041
이어서 40%메탄올 6
Figure kpo00042
로 용출시켜서 6분획으로 하고 제2에서 제6분획의 유효부분을 농축하고 동결건조함으로써 7-β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산37.1g을 얻었다.(1) 42.4 g of 7-amido-3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol-5-yl] thiomethyl-3-cepem-4-carboxylic acid Methane 1.1
Figure kpo00038
59.8 g of dicyclohexylamine was added over 5 minutes with stirring at -10 ° C. After 20 minutes, 154 g of 4-chloro-3-oxo-butyryl chloride dichloromethane solution (1.4 mol / kg) was added over 35 minutes. After 35 minutes, another 22 g was added and stirred for 20 minutes. 300 ml of water and 20 ml of 5N-HCI were added to the solution, stirred at 25 ° C. for 30 minutes, filtered, and washed with water. The filtrate and washings were washed with dichloromethane, the dichloromethane layer was extracted with water, 12.5 g of thiourea was added to the combined aqueous layers, the pH was adjusted to 5.0 with sodium hydrogencarbonate, and left at room temperature for 3 hours, followed by overnight at 10 ° C. It was left to pH 5.2 with sodium bicarbonate. This solution is added to Amberlite XAD-2 (100-200mesh) 2.5
Figure kpo00039
Pass through the column filled with
Figure kpo00040
15% methanol 4 after washing with water
Figure kpo00041
40% methanol 6
Figure kpo00042
Eluted with 6 fractions, and the effective portion of the second to sixth fractions was concentrated and lyophilized to obtain 7-β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3 37.1 g of-[1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol-5-yl] thiomethyl-3-cepem-4-carboxylic acid was obtained.

(2) (1)에서 얻은 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산의 동결 건조품을 실시예 1의 (3), (4)와 동일하게 처리하여, 상기 카르본산 이염산염의 분말을 얻었다.(2) 7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl] obtained in (1). A freeze-dried product of -1H-tetrazol-5-yl] thiomethyl-3-cepem-4-carboxylic acid was treated in the same manner as in (3) and (4) of Example 1 to obtain a powder of the carboxylic acid dihydrochloride. Got it.

[실시예 11]Example 11

1.5N-HCI 3ml과 n-프로판을 3ml의 혼합액을 10℃에서 교반하면서 7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산 0.53g이어서 n-프로판을 9ml을 첨가하여서 10℃로 5시간 교반한 후 n -프로판을 9ml을 첨가하여 5℃에서 하루밤 방치하였다. 추출된 결정을 여취하여 대기중에서 건조시킨 후 상기 카르본산의 이염산염 결정 0.50g을 얻었다.7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [with a mixture of 3 ml of 1.5N-HCI and 3 ml of n-propane was stirred at 10 ° C. 0.53 g of 2-N, N-dimethylamino) ethyl] -1H-tetrazol-5-yl] thiomethyl-3-cepem-4-carboxylic acid, followed by stirring at 10 DEG C for 5 hours with 9 ml of n-propane added thereto. After 9 ml of n-propane was added and left overnight at 5 ℃. The extracted crystals were filtered off and dried in the air to obtain 0.50 g of dihydrochloride crystals of the carboxylic acid.

IR (KBr) cm-11770(β-lactam) 1670, 1190, 1170IR (KBr) cm -1 1770 (β-lactam) 1670, 1190, 1170

원소분석치(C18H23N9O4S3·2HCI·2H2O)Elemental Analysis Value (C 18 H 23 N 9 O 4 S 3 · 2HCI · 2H 2 O)

실측치 C : 33.81 H: 4.50 N : 20.11 CI : 10.98Found C: 33.81 H: 4.50 N: 20.11 CI: 10.98

계산치 C : 34.07 H : 4.61 N : 19.86 CI : 11.17Calculated C: 34.07 H: 4.61 N: 19.86 CI: 11.17

[시 험][exam]

7β-[2-(2-이미노-4-치아조린-4-일)아세트아미도]-3-[1-[2-N,N-디메틸아미노)에틸]-1H-테트라졸-5-일]치오메틸-3-세펨-4-카르본산의 나트륨염, 쌍성이온, 일염산염과 본 발명에 의하여 얻어진 이염산염의 동결 건조품(비결정성분말), 이염산염결정 및 이염산염 결정을 건조시켜서 비결정성 분말로 한 것에 대하여 각 샘플을 밀봉된 바이알중에서 50℃로 4주간 보존한바 잔류비율은 다음과 같았다.7β- [2- (2-imino-4-thiazolin-4-yl) acetamido] -3- [1- [2-N, N-dimethylamino) ethyl] -1H-tetrazol-5- Sodium salt, zwitterion, monohydrochloride and dihydrochloride of dimethyl hydrochloride and dihydrochloride obtained according to the present invention (non-crystalline ingredients), dihydrochloride and dihydrochloride crystals Regarding the qualitative powder, each sample was stored at 50 DEG C for 4 weeks in a sealed vial, and the residual ratio was as follows.

샘 플 수 분 잔류비율Sample moisture residual ratio

실시예 1-(3)의 결정 3.1% 99%Crystals of Example 1- (3) 3.1% 99%

" 1-(4)의 분말 1.9 98"1- (4) Powder 1.9 98

" 4-(2)의 동결건조품 0.50 86"4- (2) Lyophilized 0.50 86

나트륨염 " 0.48 76Sodium Salt "0.48 76

양성(쌍성)이온 " 0.50 54Positive (bipolar) ion "0.50 54

일염산염의 동결건조품 0.58 73Lyophilized Monohydrochloride 0.58 73

Claims (1)

다음 일반식(II)의 화합물과 2몰이상의 일반식 HX로 나타내는 산을 반응시킴을 특징으로 하는 다음 일반식 (I)로 나타내는 결정성세팔로스포린 유도체의 제조방법.A method for producing a crystalline cephalosporin derivative represented by the following general formula (I), characterized by reacting a compound of the following general formula (II) with an acid represented by two or more moles of general formula HX.
Figure kpo00043
Figure kpo00043
상기식중,In the above formula, x는 염소 또는 취소이고,x is chlorine or cancellation, n은 0내지 6의 수이다.n is a number from 0 to 6.
KR7701971A 1977-08-24 1977-08-24 Process for preparing cephalosporin derivatives KR830001415B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7701971A KR830001415B1 (en) 1977-08-24 1977-08-24 Process for preparing cephalosporin derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7701971A KR830001415B1 (en) 1977-08-24 1977-08-24 Process for preparing cephalosporin derivatives

Publications (2)

Publication Number Publication Date
KR830000250A KR830000250A (en) 1983-03-30
KR830001415B1 true KR830001415B1 (en) 1983-07-25

Family

ID=19204808

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7701971A KR830001415B1 (en) 1977-08-24 1977-08-24 Process for preparing cephalosporin derivatives

Country Status (1)

Country Link
KR (1) KR830001415B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101065869B1 (en) * 2008-09-05 2011-09-29 (주)티엠씨 A plating process of a wire used in a protecting cover of a wrapping cable

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101065869B1 (en) * 2008-09-05 2011-09-29 (주)티엠씨 A plating process of a wire used in a protecting cover of a wrapping cable

Also Published As

Publication number Publication date
KR830000250A (en) 1983-03-30

Similar Documents

Publication Publication Date Title
KR840001776B1 (en) Process for preparing seftazidime pentahydrate
US5407929A (en) Triazolylthiomethylthio cephalosporin hydrochhloride, its crystalline hydrate and the production of the same
JP5852562B2 (en) Novel cephem derivatives
US4146710A (en) Solid cephalosporin salt
DK148796B (en) CEPHALOSPORANIC ACID DERIVATIVES USED AS INTERMEDIATES IN THE MANUFACTURE OF OTHER CEPHALOSPORANIC ACID DERIVATIVES
US4006138A (en) Crystalline form of sodium O-formylcefamandole
KR830001415B1 (en) Process for preparing cephalosporin derivatives
EP0497978B1 (en) Cephalosporin compounds and production thereof
JP4656798B2 (en) Cephem compound
KR880001299B1 (en) Process for preparing sodium 7beta-(2d-2amino-2-carboxyethlthioacetamido)-7alpha-methoxy-3-(-methyl-1h-tetrazol-5-yl)thiomethyl-3-cephem-4-carboxyl-ateheptahydrate
JPS58103392A (en) Novel derivatives of cephalosporin substituted with thiomethylhetero ring group at 3-position, manufacture and pharmaceutical composition
KR20050121209A (en) Novel crystal of 7-[2-(2-aminothiazole-4-yl)-2-hydroxyiminoacetamido-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof
JPH0354673B2 (en)
US4959469A (en) Crystalline cephalosporin compounds
JPS61263985A (en) Cephalosporin derivative
US5068322A (en) Crystalline cephalosporin compounds
KR890000787B1 (en) Process for oreoaring injection containing cephalosporin derivatives
WO2008050871A1 (en) Crystalline carbapenem compounds
JPH0692970A (en) Triazolythionmethylthiocephalosporin hydrochloride, its hydrare crystal and production thereof
KR950010084B1 (en) The preparing process for crystallic cephal sporin compounds
US4497811A (en) 1-Oxadethiacephalosporin compound and antibacterial agent containing the _same
EP0098615B1 (en) 1-oxadethiacephalosporin compound and antibacterial agent containing the same
KR0156275B1 (en) Process for preparation of ceftazidime pentahydrate
JPS63141985A (en) Novel cephalosporine derivative having improved pharmacokinetic characteristic, its production and drug composition
EP0300423A2 (en) Cephalosporin compound, method of its production and composition for prevention and treatment of bacterial infectious diseases